Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective
Journal of Medical Economics | March 24, 2018 | Volume: 21 | Issue: 7 | Pages: 666-675
10.1080/13696998.2018.1457533